Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. (Q48382207)

11 February 2018

title

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. (English)

1 reference

11 February 2018

1 reference

3

1 reference

11 February 2018

Nelson Leung

6

1 reference

11 February 2018

Morie A Gertz

1

M A Gertz

1 reference

11 February 2018

Martha Q Lacy

2

M Q Lacy

1 reference

11 February 2018

Francis K Buadi

8

F K Buadi

1 reference

11 February 2018

David Dingli

5

D Dingli

1 reference

11 February 2018

author name string

S K Kumar

4

1 reference

11 February 2018

W J Hogan

7

1 reference

11 February 2018

S R Hayman

9

1 reference

11 February 2018

language of work or name

English

0 references

publication date

10 September 2012

1 reference

11 February 2018

Bone Marrow Transplantation

published in

1 reference

11 February 2018

volume

48

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

page(s)

557-561

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1038/bmt.2012.170

exact match

0 references

cites work

Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Pitfalls in the diagnosis of primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Comparison of hematopoietic progenitor cell collections using the COBE Spectra version 7 and Amicus version 3.1 for patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Stem cell transplantation for the management of primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

7 January 2021

Impact of kidney dysfunction on plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute heart failure

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

7 January 2021

Advances in the autologous and allogeneic transplantation strategies for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

7 January 2021

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

7 January 2021

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

7 January 2021

Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.170

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.170

1 reference

11 February 2018

PubMed ID

22964596

1 reference

11 February 2018